J.L. Geiger

3.7k total citations · 1 hit paper
92 papers, 1.3k citations indexed

About

J.L. Geiger is a scholar working on Otorhinolaryngology, Oncology and Surgery. According to data from OpenAlex, J.L. Geiger has authored 92 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Otorhinolaryngology, 45 papers in Oncology and 27 papers in Surgery. Recurrent topics in J.L. Geiger's work include Head and Neck Cancer Studies (52 papers), Cancer Diagnosis and Treatment (14 papers) and Nonmelanoma Skin Cancer Studies (14 papers). J.L. Geiger is often cited by papers focused on Head and Neck Cancer Studies (52 papers), Cancer Diagnosis and Treatment (14 papers) and Nonmelanoma Skin Cancer Studies (14 papers). J.L. Geiger collaborates with scholars based in United States, Canada and Australia. J.L. Geiger's co-authors include Julie E. Bauman, Jennifer R. Grandis, Shlomo A. Koyfman, Eric Lamarre, David J. Adelstein, Nofisat Ismaila, Jimmy J. Caudell, N.M. Woody, Joseph Scharpf and Paul Swiecicki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

J.L. Geiger

83 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of Salivary Gland Malignancy: ASCO Guideline

2021 206 citations J.L. Geiger, Nofisat Ismaila et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.L. Geiger United States	16	681	526	469	243	235	92	1.3k
Petr Szturz Czechia	18	494 0.7×	427 0.8×	307 0.7×	350 1.4×	269 1.1×	85	1.2k
Lara Alessandrini Italy	17	284 0.4×	136 0.3×	237 0.5×	199 0.8×	217 0.9×	69	827
Steven E. Vogl United States	21	749 1.1×	250 0.5×	458 1.0×	554 2.3×	229 1.0×	55	1.4k
Antonio Jirillo Italy	15	595 0.9×	456 0.9×	424 0.9×	307 1.3×	137 0.6×	60	1.1k
Scott A. Kono United States	15	815 1.2×	250 0.5×	485 1.0×	674 2.8×	375 1.6×	22	1.4k
L. Iglesias Spain	13	408 0.6×	115 0.2×	96 0.2×	210 0.9×	157 0.7×	36	775
A. Trotti United States	7	709 1.0×	1.4k 2.8×	918 2.0×	637 2.6×	491 2.1×	15	2.2k
Yabing Cao China	15	350 0.5×	122 0.2×	131 0.3×	135 0.6×	191 0.8×	52	811
Rebecca Feldman United States	19	568 0.8×	41 0.1×	188 0.4×	310 1.3×	262 1.1×	68	983
Luciano de Souza Viana Brazil	18	492 0.7×	225 0.4×	137 0.3×	396 1.6×	342 1.5×	37	968

Countries citing papers authored by J.L. Geiger

Since Specialization

Citations

This map shows the geographic impact of J.L. Geiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.L. Geiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.L. Geiger more than expected).

Fields of papers citing papers by J.L. Geiger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.L. Geiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.L. Geiger. The network helps show where J.L. Geiger may publish in the future.

Co-authorship network of co-authors of J.L. Geiger

This figure shows the co-authorship network connecting the top 25 collaborators of J.L. Geiger. A scholar is included among the top collaborators of J.L. Geiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.L. Geiger. J.L. Geiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stewart, Matthew C. & J.L. Geiger. (2025). Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations. Cancer Management and Research. Volume 17. 211–217. 3 indexed citations

Ullah, Fauzia, et al.. (2024). Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges. JCO Oncology Practice. 20(12). 1588–1595. 11 indexed citations

Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. Journal of Clinical Oncology. 43(5). 578–588. 9 indexed citations

Fan, Cong, J.L. Geiger, Tamara A. Sussman, et al.. (2024). Plasma circulating tumor DNA in patients with cutaneous squamous cell carcinoma: Initial experience.. Journal of Clinical Oncology. 42(16_suppl). e15034–e15034. 1 indexed citations

Yom, Sue S., Janet Harris, Jimmy J. Caudell, et al.. (2024). Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 120(2). S2–S3. 21 indexed citations

Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202. International Journal of Radiation Oncology*Biology*Physics. 118(5). e18–e18. 1 indexed citations

Yang, Kailin, Shauna R. Campbell, N.M. Woody, et al.. (2023). Comparison of real‐world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials. Head & Neck. 45(4). 862–871. 3 indexed citations

Hoda, Raza S., et al.. (2023). ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy. Modern Pathology. 36(10). 100273–100273. 9 indexed citations

Dima, Danai, Robert R. Lorenz, B. Prendes, et al.. (2023). Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement. Head & Neck. 45(8). 2149–2154. 3 indexed citations

10.

Geiger, J.L., et al.. (2022). Impact of continuous infusions of opioids on discharge opioid prescriptions. Journal of Opioid Management. 18(3). 223–228.

11.

Geiger, J.L., et al.. (2022). Agree to Disagree? Equianalgesic Consensus Amongst Hospice and Palliative Providers (S555). Journal of Pain and Symptom Management. 63(5). 936–937.

12.

Kunte, Siddharth, Wei Wei, Christian Nasr, et al.. (2022). Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes. Anticancer Research. 42(5). 2531–2539. 6 indexed citations

13.

Geiger, J.L., Nofisat Ismaila, Beth M. Beadle, et al.. (2021). Management of Salivary Gland Malignancy: ASCO Guideline. Journal of Clinical Oncology. 39(17). 1909–1941. 206 indexed citations breakdown →

14.

Bennani, N. Nora, Aung M. Tun, Kenneth R. Carson, et al.. (2021). Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma Myeloma & Leukemia. 22(4). e250–e260. 1 indexed citations

15.

Smile, Timothy D., David D. Xiong, Brian Gastman, et al.. (2021). Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis. Anticancer Research. 41(1). 289–295. 6 indexed citations

16.

Broughman, James R., David D. Xiong, Benjamin J. Moeller, et al.. (2020). Rethinking the 10‐pack‐year rule for favorable human papillomavirus–associated oropharynx carcinoma: A multi‐institution analysis. Cancer. 126(12). 2784–2790. 10 indexed citations

17.

Canavan, Joycelin, C.A. Reddy, Deborah J. Chute, et al.. (2020). Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer. Oral Oncology. 103. 104585–104585. 7 indexed citations

18.

Ward, Matthew C., Joseph Scharpf, Eric Lamarre, et al.. (2019). Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. The Laryngoscope. 130(10). 2372–2377. 6 indexed citations

19.

Koyfman, Shlomo A., Nikhil Joshi, Eric Lamarre, et al.. (2018). Validating the AJCC 8th Edition of the Oral Cavity Cancer Staging System: A Multi-institutional Collaborative Study. International Journal of Radiation Oncology*Biology*Physics. 102(3). S22–S22. 3 indexed citations

20.

Juloori, Aditya, Shlomo A. Koyfman, J.L. Geiger, et al.. (2018). Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. Anticancer Research. 38(6). 3543–3549. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact